Mediators of exocrine pancreatic secretion induced by intraduodenal application of bile and taurodeoxycholate in man.
The aim of the study was to investigate whether cholecystokinin, neurotensin, and cholinergic mechanisms act as mediators of bile salt-stimulated exocrine pancreatic secretion. Ten fasting healthy subjects provided with a double-lumen tube received 2, 4, and 6 g cattle bile and 200, 400, and 600 mg Na-taurodeoxycholate (TDC) into the duodenum at 65-min intervals, respectively. The application of TDC was repeated in another 10 subjects after intravenous bolus injection of 2.5 micrograms/kg b.w. atropine followed by continuous infusion of 5 micrograms/kg.h. Secretions of volume, bicarbonate, trypsin, and lipase were determined in 10-min fractions of duodenal juice. Plasma samples were analysed for cholecystokinin-like immunoreactivity (CCK-LI) and neurotensin with radioimmunoassays. Volume, bicarbonate, trypsin, and lipase secretion rates were significantly increased by 4 g and 6 g bile and by all doses of TDC. Incremental volume and bicarbonate output was dose-dependently enhanced by bile and TDC, and trypsin and lipase output by bile. Atropine significantly decreased the baseline values and all responses to TDC. Plasma concentrations and integrated CCK-LI and neurotensin significantly increased after 4 and 6 g bile and after 400 and 600 mg TDC. Atropine did not significantly influence peptide release. It is concluded that both hydrokinetic and ecbolic pancreatic secretion stimulated by intraduodenal bile and TDC are dependent on a cholinergic tone. CCK and probably also neurotensin act as further mediators of the ecbolic effect.
Riepl
R L
RL
Medizinische Klinik, Klinikum Innenstadt, University of Munich, Germany.
Reichardt
B
B
Rauscher
J
J
Tzavella
K
K
Teufel
J
J
Lehnert
P
P
D000818:Animals; D001285:Atropine / Q000008:administration & dosage / Q000494:pharmacology; D001639:Bicarbonates / Q000378:metabolism; D001646:Bile / Q000502:physiology*; D002417:Cattle; D002766:Cholecystokinin / Q000097:blood*; D004386:Duodenum / Q000502:physiology*; D005215:Fasting; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008049:Lipase / Q000378:metabolism*; D009496:Neurotensin / Q000097:blood; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D012016:Reference Values; D012044:Regression Analysis; D013657:Taurodeoxycholic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D014357:Trypsin / Q000378:metabolism*
D001639:Bicarbonates; D009496:Neurotensin; D013657:Taurodeoxycholic Acid; D001285:Atropine; D002766:Cholecystokinin; D008049:Lipase; D014357:Trypsin